Key statistics dashboard for Puma Biotechnology, Inc. (PBYI). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Puma Biotechnology, Inc. is a biopharmaceutical company dedicated to the global development and commercialization of treatments aimed at advancing cancer care. Its lead drug candidate, orally administered neratinib (PB272), targets a range of indications. These include patients with early-stage HER2-overexpressed/amplified breast cancer, as well as adults suffering from advanced or metastatic HER2-positive breast cancer when used in combination with capecitabine.
Stock Data
| Price | $9.39 |
| Market Cap | $478M |
| Enterprise Value | $446.2M |
| Beta | 1.18 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | 17.51 |
| Price / Book | 3.45 |
| P/S | 2.07 |
| EV/EBITDA | 9.36 |
| EV/Sales | 1.93 |
| EV/FCF | 10.84 |
| P/FCF | 11.61 |
| Earnings Yield | 5.59% |
| FCF Yield | 8.61% |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 74.83% |
| EBIT Margin | 15.00% |
| EBITDA Margin | 20.61% |
| Operating Margin | 13.16% |
| Net Margin | 11.55% |
| Return on Equity | 20.85% |
| Return on Assets | 13.86% |
| Return on Invested Capital | 18.20% |
| Return on Capital Employed | 21.30% |
Financial Health
| Current Ratio | 2.91 |
| Quick Ratio | 2.64 |
| Cash Ratio | 0.73 |
| Debt / Equity | 0.03 |
| Debt / Assets | 2.50% |
| Net Debt / EBITDA | -0.67 |
| Interest Coverage | 8.65 |
| Piotroski F-Score | 7 |
| Altman Z-Score | -4.16 |
Per-Share Data
| Revenue per share | 4.54 |
| Book Value per share | 2.72 |
| Cash per share | 1.84 |
| FCF per share | 0.81 |
| Tangible Book Value per share | 2.00 |
| Dividend per share | 0.00 |
Analyst Consensus
| Strong Buy | 0 |
| Buy | 8 |
| Hold | 8 |
| Sell | 4 |
| Strong Sell | 0 |
| Total analysts | 20 |
| Avg rating (1-5) | 0.20 |
Related companies: ABEO · ALLO · ARCT · AVIR · ELDN · HUMA · SGMT
Explore sector: Healthcare · Biotechnology
More sections of PBYI: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks